Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $53.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its target price hoisted by research analysts at Wedbush from $50.00 to $53.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s price target suggests a potential upside of 21.84% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Canaccord Genuity Group started coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They issued a “buy” rating and a $62.00 price target on the stock. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Finally, The Goldman Sachs Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $54.14.

Kiniksa Pharmaceuticals International Trading Down 8.2%

KNSA stock opened at $43.50 on Wednesday. The firm has a 50 day moving average of $42.87 and a 200-day moving average of $39.64. The company has a market cap of $3.30 billion, a price-to-earnings ratio of 96.67 and a beta of 0.06. Kiniksa Pharmaceuticals International has a 12-month low of $18.25 and a 12-month high of $49.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.12). The firm had revenue of $202.13 million during the quarter, compared to analysts’ expectations of $200.86 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The business’s revenue for the quarter was up 65.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.12) earnings per share. Sell-side analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Mark Ragosa sold 17,845 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $43.28, for a total value of $772,331.60. Following the completion of the transaction, the chief financial officer directly owned 12,086 shares in the company, valued at approximately $523,082.08. This represents a 59.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Barry D. Quart sold 2,690 shares of the stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $45.00, for a total value of $121,050.00. Following the transaction, the director owned 12,546 shares in the company, valued at $564,570. This trade represents a 17.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 123,623 shares of company stock valued at $5,236,389 over the last quarter. Company insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC raised its stake in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares during the period. Osaic Holdings Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth $31,000. USA Financial Formulas purchased a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth $32,000. Smartleaf Asset Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth $36,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at $41,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Company issued robust ARCALYST 2026 net product revenue guidance of $900M–$920M, signaling continued commercial traction and market penetration. GlobeNewswire: Financial Results and Guidance
• Positive Sentiment: Revenue momentum: Q4 ARCALYST net product revenue was $202.1M and full‑year ARCALYST revenue reached $677.6M (FY2025), and total company revenue grew ~65% YoY — evidence of strong commercial execution. GlobeNewswire: Revenue Details
• Neutral Sentiment: Pipeline timing: KPL‑387 Phase 2 recurrent pericarditis data expected in 2H‑2026 and a KPL‑1161 Phase 1 trial planned to start by end‑2026 — these are important catalysts but still months away. GlobeNewswire: Pipeline Update
• Neutral Sentiment: Unusual options activity has been noted by some outlets — could reflect speculation or hedging and may amplify intraday moves, but not a fundamental change. MSN: Options Activity
• Negative Sentiment: Q4 EPS missed expectations: reported $0.17 vs. consensus ~$0.29 — the EPS shortfall (and lower-than-expected profitability metrics) was the primary driver of the selloff despite revenue beating estimates slightly. Zacks: EPS Miss
• Negative Sentiment: Valuation and near‑term profitability concerns: the stock trades at a high multiple relative to current profitability (P/E elevated) and some analysts still expect negative FY EPS, making the name sensitive to execution and margin trends. MarketBeat: Stock Profile & Estimates

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.